Related Experiment Video
Updated: May 13, 2026
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Regulatory and reimbursement innovation.
Rachel A Lindor1, Scott J Allocco, Lee Cheatham
1Center for Law, Science, and Innovation, Sandra Day O'Connor College of Law, Arizona State University, Tempe, AZ 85287, USA.
Science Translational Medicine
|March 15, 2013
Summary
Coverage with evidence development and parallel review streamline the regulatory and reimbursement processes for novel molecular diagnostics. These approaches facilitate market access for innovative diagnostic technologies.
Area of Science:
- Biomedical science
- Health policy
- Regulatory science
Background:
- Molecular diagnostics offer significant potential for personalized medicine and improved patient outcomes.
- Navigating the complex regulatory and reimbursement landscape presents a major challenge for the adoption of new diagnostic technologies.
- Existing pathways may not adequately address the unique evidence requirements and rapid innovation cycles of molecular diagnostics.
Purpose of the Study:
- To evaluate the effectiveness of Coverage with Evidence Development (CED) and parallel agency review in facilitating the regulation and reimbursement of molecular diagnostics.
- To identify best practices and potential improvements for these integrated regulatory and market access strategies.
- To understand the impact of these approaches on timely patient access to innovative diagnostic tools.
Main Methods:
- Analysis of existing CED and parallel review programs for molecular diagnostics.
- Review of regulatory submissions and reimbursement decisions.
- Case studies of specific molecular diagnostic technologies utilizing these pathways.
- Stakeholder interviews with developers, regulators, and payers.
Main Results:
- Coverage with Evidence Development (CED) and parallel review processes demonstrate a positive correlation with expedited regulatory approval and successful reimbursement.
- These integrated approaches can reduce time-to-market and enhance predictability for developers.
- Successful implementation requires strong collaboration between regulatory bodies, healthcare providers, and payers.
Conclusions:
- Coverage with Evidence Development (CED) and parallel review are valuable tools for optimizing the regulatory and reimbursement pathways for molecular diagnostics.
- These strategies promote innovation by providing clearer routes for market access.
- Continued refinement and adoption of these integrated approaches are crucial for advancing personalized medicine.
Related Concept Videos
01:29Issues And Trends In Healthcare Delivery System
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
01:30Health Information Technology and Healthcare Information System
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).